These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2204 related items for PubMed ID: 22285209

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
    Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S.
    Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
    [Abstract] [Full Text] [Related]

  • 13. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
    Hochhaus A, Müller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP.
    Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, Beverloo BB, den Boer ML, Pieters R, Reinhardt D, Dworzak M, Rosenberg J, Manos G, Agrawal S, Strauss L, Baruchel A, Kearns PR.
    J Clin Oncol; 2013 Jul 01; 31(19):2460-8. PubMed ID: 23715577
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.
    N Engl J Med; 2006 Jun 15; 354(24):2531-41. PubMed ID: 16775234
    [Abstract] [Full Text] [Related]

  • 19. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C.
    Am J Health Syst Pharm; 2007 Dec 15; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [Abstract] [Full Text] [Related]

  • 20. Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.
    Keating GM, Lyseng-Williamson KA, McCormack PL, Keam SJ.
    BioDrugs; 2013 Jun 15; 27(3):275-9. PubMed ID: 23549840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 111.